Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Amortizatization of Intangibles (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Amortizatization of Intangibles for 7 consecutive years, with $622000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles rose 8.74% year-over-year to $622000.0, compared with a TTM value of $2.4 million through Dec 2025, up 32.42%, and an annual FY2025 reading of $2.4 million, up 32.42% over the prior year.
  • Amortizatization of Intangibles was $622000.0 for Q4 2025 at Keros Therapeutics, up from $609000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $622000.0 in Q4 2025 and bottomed at $99000.0 in Q1 2021.
  • Average Amortizatization of Intangibles over 5 years is $362150.0, with a median of $340000.0 recorded in 2023.
  • The sharpest move saw Amortizatization of Intangibles soared 157.14% in 2023, then tumbled 35.06% in 2024.
  • Year by year, Amortizatization of Intangibles stood at $198000.0 in 2021, then skyrocketed by 62.12% to $321000.0 in 2022, then increased by 4.36% to $335000.0 in 2023, then surged by 70.75% to $572000.0 in 2024, then rose by 8.74% to $622000.0 in 2025.
  • Business Quant data shows Amortizatization of Intangibles for KROS at $622000.0 in Q4 2025, $609000.0 in Q3 2025, and $595000.0 in Q2 2025.